ALK and non-small cell lung carcinoma: The antitumour activity of crizotinib in cancer clinical trials has been significant [25, 28], leading to the Food and Drug Administration (FDA) approval as an integral addition to clinical treatment of patients with non-small cell lung cancer (NSCLC) carrying ALK translocations [29, 30].